Sachie Hirai

Sachie Hirai

Auto-generated profile, based on publicly available information

Sachie Hirai

Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MYMiki Yamaguchi
Miki Yamaguchi
SHSachie Hirai
Sachie Hirai
YTYusuke Tanaka
Yusuke Tanaka
TSToshiyuki Sumi
Toshiyuki Sumi
MTMakoto Tada
Makoto Tada
YSYuji Sakuma
Yuji Sakuma

19 August 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YSYuji Sakuma
Yuji Sakuma
SHSachie Hirai
Sachie Hirai
TSToshiyuki Sumi
Toshiyuki Sumi
TNToshiro Niki
Toshiro Niki
MYMiki Yamaguchi
Miki Yamaguchi
EGFR-mutant lung adenocarcinoma (LUAD) mostly depends on EGFR for survival and consequently responds well to EGFR inhibitors. However, resistance to the drugs develops almost universally during treatment. We previously demonstrated that EGFR-mutant LUAD cell lines, HCC827 and H1975, have subpopulations of cells, which we termed HCC827 GR2 and H1975 WR7 cells, that can thrive independently of EGFR signaling. These EGFR-independent EGFR-mutant cancer cells are difficult to treat because they lack sensitivity to EGFR inhibitors. Therefore, the development of novel strategies to target EGFR-independent EGFR-mutant LUAD is particularly important. We found that high expression of kinesin family member 11 (KIF11) correlated with poor survival in patients with LUAD. We also observed that KIF11 silencing caused cell cycle arrest at G2/M in HCC827 GR2 and H1975 WR7 cells. Furthermore, dual silencing of KIF11 plus BCL2L1, an anti-apoptotic BCL2 family member, in these two EGFR-independent sublines resulted in marked apoptosis levels. Dual inhibition of KIF11 plus BCL2L1 also induced apoptosis in HCC827 and H1975 parental cells and a KRAS-mutant LUAD cell line, H441. These findings collectively suggest that dual inhibition of KIF11 plus BCL2L1 may be a new approach for the treatment of LUAD.

1 September 2021 in Experimental Cell Research
Verified
Journal Article
Open access
YSYuji Sakuma
Yuji Sakuma
SHSachie Hirai
Sachie Hirai
TSToshiyuki Sumi
Toshiyuki Sumi
MTMakoto Tada
Makoto Tada
TKTakashi Kojima
Takashi Kojima
MYMiki Yamaguchi
Miki Yamaguchi
MCL1 is an anti-apoptotic BCL2 family member that is often overexpressed in various malignant tumors. However, few reports have described the role of MCL1 in squamous cell carcinoma (SqCC) derived from airways including the lung. In this study, we examined whether MCL1 could be a novel druggable target for airway-derived SqCC, for which effective molecular targeted drugs are unavailable. We searched the Kaplan-Meier Plotter database and found that high MCL1 mRNA expression was significantly associated with shorter survival in patients with lower airway (lung) or upper airway (head and neck) derived SqCC. We also explored the Expression Atlas database and learned that authentic lung SqCC cell lines expressing both TP63 and KRT5 mRNA were extremely sparse among the publicly available "lung SqCC cell lines", with an exception being HARA cells. HARA cells were highly dependent on MCL1 for survival, and MCL1-depleted cells were not able to grow, and even declined in number, upon docetaxel (DTX) exposure in vitro and in vivo. Similar in vitro experimental findings, including those in a 3D culture model, were also obtained using Detroit 562 pharyngeal SqCC cells. These findings suggested that combined treatment with MCL1 silencing plus DTX appears highly effective against airway-derived SqCC.

1 May 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SHSachie Hirai
Sachie Hirai
MTMakoto Tada
Makoto Tada
MYMiki Yamaguchi
Miki Yamaguchi
TNToshiro Niki
Toshiro Niki
YSYuji Sakuma
Yuji Sakuma

14 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SHSachie Hirai
Sachie Hirai
MIMasashi Idogawa
Masashi Idogawa
TSToshiyuki Sumi
Toshiyuki Sumi
MYMiki Yamaguchi
Miki Yamaguchi
TNToshiro Niki
Toshiro Niki
YSYuji Sakuma
Yuji Sakuma

19 February 2022 in Experimental Cell Research
Verified
Journal Article
Open access
MYMiki Yamaguchi
Miki Yamaguchi
SHSachie Hirai
Sachie Hirai
MIMasashi Idogawa
Masashi Idogawa
HUHiroaki Uchida
Hiroaki Uchida
YSYuji Sakuma
Yuji Sakuma
Although MET tyrosine kinase inhibitors (TKIs) are generally effective against non-small cell lung carcinoma (NSCLC) with MET exon 14 skipping mutations (MET delta ex14), resistance to MET TKIs can occur, indicating the need to develop other therapeutic options. We found that Hs-746 T cells, which harbor MET delta ex14 plus amplification, were able to survive and grow in the absence of MET signaling, exhibiting primary resistance to MET TKIs. We also found a moderately positive correlation between MET and anthrax toxin receptor 2 (ANTXR2) mRNA expression in NSCLC cell lines using data from the Cancer Dependency Map database. As expected, Hs-746 T cells were positive for ANTXR2 expression. We used an antibody-drug conjugate (ADC) analog in the form of an anti-ANTXR2 monoclonal antibody, H8R23, conjugated to DT3C recombinant protein which consists of diphtheria toxin (DT) lacking the receptor-binding domain but containing the C1, C2, and C3 domains of streptococcal protein G (3C). H8R23-DT3C conjugates, which function in vitro like an ADC, induced Hs-746 T cells to undergo apoptosis, resulting in decreased viability. These findings collectively suggest that an ADC targeting ANTXR2 could be effective for the treatment of MET & UDelta;ex14-positive NSCLC.